Ness Ziona ISRAEL, February 6, 2005 - Foamix Ltd., a leader in developing innovative topical delivery systems, enters new state-of-the-art facility.

Foamix Ltd., an innovative drug development company specializing in the development and commercialization of proprietary topical foam products for the prescription, OTC and cosmetics markets, announced today that its new facility in the Weizmann Science Park in Rehovoth, Israel is now fully operational.

"Our new 1,200m2 (12,000ft2) facility provides us with the full capability to meet the requirements of our existing pharma development collaborations, in-house projects and leaves us reserve for pipeline projects," declared Foamix's COO, Meir Eini. "This facility fully complements the highly experienced and skilled team of development, clinical and regulatory professionals which we have assembled. We now have the ability to handle the complete process from initial formulation studies of foam-delivered actives and sterile cGMP prototype development through to new drug applications housed in our own facility and under our full control," he continued.

About Foamix: Foamix Ltd. specializes in the development and commercialization of proprietary foam products for Dermatology, Gynecology, Cosmetics, Wound-Care and Burn-Healing. Foamix develops products in-house which are available for licensing and also co-operates with leading pharmaceutical companies in the development of foam-based products for the delivery of proprietary actives.

The Weizmann Science Park, situated adjacent to the world-renowned Weizmann Institute of Science in Rehovoth Israel, is a leading life-sciences industrial park in Israel.